Fox Chase Cancer Center

In June 2007, Dr. Seiden assumed the position of President and Chief Executive Officer of the Fox Chase Cancer Center. As President, he has the responsibility for all strategic planning, finances and operations within the Center and serves as the Principal Investigator for the NCI-sponsored Comprehensive Cancer Center grant. He also serves as the current principal investigator for the NCI-funded ovarian SPORE grant. Dr. Seiden earned his undergraduate degree at Oberlin College and graduated magna cum laude in Chemistry. He subsequently was accepted to the Medical Science Training Program at Washington University Medical School and completed an MD and PhD in 1986 with his principal area of research in the field of immunology. He entered a medical internship at the Massachusetts General Hospital and subsequently completed a residency and chief residency in Medicine at MGH followed by clinical oncology training at the Dana Farber Cancer Institute. Once completing his clinical training he worked as a postdoctoral fellow in the laboratory of Dr. Jeffrey Sklar in the Department of Pathology at Brigham and Women's Hospital working on topics in molecular diagnostics. In 1994, he joined the faculty of the Massachusetts General Hospital and the MGH Cancer Center in the Division of Hematology and Oncology. Over the ensuing thirteen years, he held a number of positions including Deputy Chief of the Division of Hematology and Oncology, Director of the Hematology/Oncology Training Program, Director of the Clinical Risk Assessment Program within the Cancer Center, and most recently Chief of the Clinical Research Unit within the Division of Cancer Medicine. In 1995, he was named the Chair of the Clinical Research Committee for the Gynecologic Cancer Program within the Dana Farber/Harvard Cancer Center and in 2004 he became the Director for Gynecologic Cancers Program for this NCI-supported program. His research interests at MGH included translational research in gynecologic malignancies with a focus on ovarian cancer. At MGH, he divided his time between patient care and clinical research focused on ovarian cancer, and bench-based molecular research looking to better define the molecular mechanisms of drug resistance.